[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2169074T3 - Factor vii modificado para inhibir la reestenosis vascular o el deposito de plaquetas. - Google Patents

Factor vii modificado para inhibir la reestenosis vascular o el deposito de plaquetas.

Info

Publication number
ES2169074T3
ES2169074T3 ES94918092T ES94918092T ES2169074T3 ES 2169074 T3 ES2169074 T3 ES 2169074T3 ES 94918092 T ES94918092 T ES 94918092T ES 94918092 T ES94918092 T ES 94918092T ES 2169074 T3 ES2169074 T3 ES 2169074T3
Authority
ES
Spain
Prior art keywords
factor vii
resenosis
vascular
inhibit
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94918092T
Other languages
English (en)
Inventor
Kathleen L Berkner
Lars Christian Petersen
Charles E Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Novo Nordisk AS
Original Assignee
Novo Nordisk Health Care AG
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care AG, Novo Nordisk AS filed Critical Novo Nordisk Health Care AG
Application granted granted Critical
Publication of ES2169074T3 publication Critical patent/ES2169074T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA ZONA CATALITICA ACTIVA DEL FACTOR VII SE MODIFICA PARA PRODUCIR UN COMPUESTO QUE INTERRUMPA EFECTIVAMENTE LA CASCADA DE COAGULACION DE LA SANGRE. LA MODIFICACION DA COMO RESULTADO UN FACTOR VIIA SUBSTANCIALMENTE INCAPAZ DE ACTIVAR LOS FACTORES X U XI DEL PLASMA. TAMBIEN SE PRESENTAN COMPOSICIONES FARMACEUTICAS DEL FACTOR VII MODIFICADO QUE SE UTILIZAN PARA TRATAR UNA VARIEDAD DE ENFERMEDADES RELACIONADAS CON LA COAGULACION.
ES94918092T 1993-05-21 1994-05-23 Factor vii modificado para inhibir la reestenosis vascular o el deposito de plaquetas. Expired - Lifetime ES2169074T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6572593A 1993-05-21 1993-05-21

Publications (1)

Publication Number Publication Date
ES2169074T3 true ES2169074T3 (es) 2002-07-01

Family

ID=22064676

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94918092T Expired - Lifetime ES2169074T3 (es) 1993-05-21 1994-05-23 Factor vii modificado para inhibir la reestenosis vascular o el deposito de plaquetas.

Country Status (11)

Country Link
EP (1) EP0699075B1 (es)
JP (1) JPH08510746A (es)
AT (1) ATE210458T1 (es)
AU (1) AU703110B2 (es)
CA (1) CA2162726A1 (es)
DE (1) DE69429429T2 (es)
DK (1) DK0699075T3 (es)
ES (1) ES2169074T3 (es)
HU (1) HU219682B (es)
PT (1) PT699075E (es)
WO (1) WO1994027631A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AU783512B2 (en) 2000-02-11 2005-11-03 Bayer Healthcare Llc Factor VII or VIIa-like molecules
DK2236152T3 (da) 2000-04-12 2014-07-07 Novozymes Biopharma Dk As Albuminfusionsproteiner
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
JP4361728B2 (ja) * 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
KR100882482B1 (ko) 2000-09-13 2009-02-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 사람 응고 인자 ｖｉｉ 변이체
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
CA2441580A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP1443956A2 (en) * 2001-11-02 2004-08-11 Novo Nordisk Health Care AG Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
PT1499719E (pt) 2002-04-30 2011-02-09 Bayer Healthcare Llc Variantes polipeptídicas do factor vii ou viia
EP2283856B1 (en) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabilised solid compositions of factor VIIa polypeptides
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
DK1549677T3 (da) * 2002-09-30 2011-07-18 Bayer Healthcare Llc FVII- eller FVIIa-varianter med forøget koagulationsaktivitet
WO2004041302A1 (en) * 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
EP2085470B1 (en) 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII or FVIIa variants
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
CN1780638B (zh) 2003-05-23 2010-04-14 诺和诺德医疗保健公司 氧化硅涂层玻璃作为容器内壁材料的用途及以该材料作内壁的容器
CN1839203B (zh) 2003-06-19 2011-11-16 拜耳医药保健有限公司 因子VII或VIIa的GLA结构域变体
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
AU2004264282B2 (en) 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
WO2006035060A2 (en) * 2004-09-29 2006-04-06 Novo Nordisk Health Care Ag Purification of a bulk of a factor vii polypeptide by fractionated elution from an anion-exchange material
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
AU2006203792B2 (en) 2005-01-10 2011-11-03 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
WO2008124406A2 (en) 2007-04-03 2008-10-16 Neose Technologies, Inc. Methods of treatment using glycopegylated g-csf
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
AU2017206445B2 (en) 2016-01-15 2019-07-18 Rigshospitalet Quantitative pet imaging of tissue factor expression using 18F-labled active site inhibited factor VII
EP3541432A4 (en) 2016-11-17 2020-08-05 Minerva Imaging ApS 177 LU MARKED FACTOR VII INHIBITED BY ACTIVE LOCATION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131292T2 (de) * 1990-01-29 1999-09-30 Zymogenetics, Inc. Antikoagulierende proteine
EP0575464B1 (en) * 1991-02-28 2004-08-11 Zymogenetics, Inc. Modified factor vii

Also Published As

Publication number Publication date
DE69429429D1 (de) 2002-01-24
EP0699075A1 (en) 1996-03-06
DK0699075T3 (da) 2002-03-11
JPH08510746A (ja) 1996-11-12
PT699075E (pt) 2002-05-31
EP0699075B1 (en) 2001-12-12
HU9503312D0 (en) 1996-01-29
HU219682B (hu) 2001-06-28
DE69429429T2 (de) 2002-05-16
HUT73329A (en) 1996-07-29
AU6956094A (en) 1994-12-20
CA2162726A1 (en) 1994-12-08
WO1994027631A1 (en) 1994-12-08
ATE210458T1 (de) 2001-12-15
AU703110B2 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
ES2169074T3 (es) Factor vii modificado para inhibir la reestenosis vascular o el deposito de plaquetas.
MX9702951A (es) Factor vii modificado.
DE69233398D1 (de) Modifizierter faktor-vii
HUP0003077A2 (hu) Módosított VII faktor
ATE177752T1 (de) Neue inhibitoren von faktor xa
EA199800043A1 (ru) Замещенные (сульфиновой кислоты, сульфоновой кислоты, сульфониламино или сульфиниламино) n-[(аминоиминометил)фенилалкил]азагетероциклил-амидные производные
ATE175876T1 (de) Verkürzter gewebsfaktor und fviia oder fvii zur aktivierung der blutgerinnung
KR920000785A (ko) 새로운 혈소판 응집 억제인자
PT727419E (pt) Compostos intermediarios para a preparacao de inibidores da protease retroviral
EA200100126A1 (ru) Производные гидроксипипеколатгидроксамовой кислоты как ингибиторы ммр
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
PT96103A (pt) Processo para a preparacao de proteinas fibrinoliticas e anti-tromboticas activaveis
MY138860A (en) Hiv protease inhibitors.
UA40578C2 (uk) Сульфоніламінопіримідини і фармацевтичний препарат на їх основі
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
AR027533A1 (es) Derivados de acido malonico, procesos para su preparacion, su uso y composiciones farmaceuticas que los contienen
ATE101796T1 (de) Blutgerinnungshemmende zusammensetzungen aus faktor xa.
McMillan et al. Phorbol esters inhibit alpha1-adrenergic receptor-stimulated phosphoinositide hydrolysis and contraction in rat aorta: Evidence for a link between vascular contraction and phosphoinositide turnover
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
FI963462A (fi) Bentsotiofeeni-, bentsofuraani- ja indolitiatsepinonit, -oksatsepinonit ja -diatsepinonit soluadheesion estäjinä ja HIV:n estäjinä
ES2180933T3 (es) Inhibidor de la serina-proteasa.
BR9813410A (pt) Composto, formulação farmacêutica, uso de um composto, e, processos de tratamento de uma condição, em que a inibição de trombina é requerida ou desejada, e para a preparação de um composto.
EA200100966A1 (ru) ЛЕЧЕНИЕ ТРОМБОЗА КОМБИНИРОВАННЫМ ПРИМЕНЕНИЕМ ИНГИБИТОРА ФАКТОРА Xa И АСПИРИНА, АКТИВАТОРА ТКАНЕВОГО ПЛАЗМИНОГЕНА (TPA), АНТАГОНИСТА GPIIB/IIIA, НИЗКОМОЛЕКУЛЯРНОГО ГЕПАРИНА ИЛИ ГЕПАРИНА
CO5160248A1 (es) Metodo para tratar copd
DE69325899D1 (de) 3-ALKYLOXY-, ARYLOXY-, ODER ARYLALKYLOXY- BENZO[b]THIOPHEN- 2-CARBOXAMIDE ALS INHIBITOREN VON ZELLADHÄSION

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 699075

Country of ref document: ES